Compare Stocks: OCS, PRGO, TRVI, and URGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCS Oculis	$8.64 -1.4%	$11.53	$8.53 ▼ $34.47	$501.24M	0.62	430,192 shs	277,216 shs
PRGO Perrigo	$14.29 +1.9%	$13.37	$9.23 ▼ $22.65	$1.98B	0.69	3.10 million shs	797,534 shs
TRVI Trevi Therapeutics	$13.92 -1.8%	$16.93	$9.28 ▼ $20.22	$1.98B	0.98	1.71 million shs	862,301 shs
URGN Urogen Pharma	$41.48 +2.3%	$43.88	$15.86 ▼ $50.81	$2.03B	1.57	800,685 shs	288,974 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCS Oculis	-6.21%	-6.91%	-28.08%	-37.96%	-49.66%
PRGO Perrigo	-4.80%	-4.58%	-2.25%	+27.64%	-37.58%
TRVI Trevi Therapeutics	-0.98%	-3.41%	-14.42%	-20.91%	+50.85%
URGN Urogen Pharma	-0.20%	-1.65%	-6.55%	+6.65%	+127.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCS Oculis	$8.64 -1.4%	$11.53	$8.53 ▼ $34.47	$501.24M	0.62	430,192 shs	277,216 shs
PRGO Perrigo	$14.29 +1.9%	$13.37	$9.23 ▼ $22.65	$1.98B	0.69	3.10 million shs	797,534 shs
TRVI Trevi Therapeutics	$13.92 -1.8%	$16.93	$9.28 ▼ $20.22	$1.98B	0.98	1.71 million shs	862,301 shs
URGN Urogen Pharma	$41.48 +2.3%	$43.88	$15.86 ▼ $50.81	$2.03B	1.57	800,685 shs	288,974 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCS Oculis	-6.21%	-6.91%	-28.08%	-37.96%	-49.66%
PRGO Perrigo	-4.80%	-4.58%	-2.25%	+27.64%	-37.58%
TRVI Trevi Therapeutics	-0.98%	-3.41%	-14.42%	-20.91%	+50.85%
URGN Urogen Pharma	-0.20%	-1.65%	-6.55%	+6.65%	+127.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OCS Oculis	2.80	Moderate Buy	$39.44	356.53% Upside
PRGO Perrigo	2.00	Hold	$19.33	35.29% Upside
TRVI Trevi Therapeutics	3.00	Buy	$27.08	94.55% Upside
URGN Urogen Pharma	2.70	Moderate Buy	$52.38	26.25% Upside

Current Analyst Ratings Breakdown

Latest OCS, PRGO, TRVI, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/18/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$26.00 ➝ $39.00
9/10/2026	URGN Urogen Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$56.00
8/25/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$23.00 ➝ $20.00
8/14/2026	TRVI Trevi Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $28.00
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00
8/7/2026	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$40.00
8/7/2026	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $30.00
8/6/2026	PRGO Perrigo	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OCS Oculis	$1.45M	345.48	N/A	N/A	$4.08 per share	2.12
PRGO Perrigo	$4.25B	0.47	$5.12 per share	2.79	$21.33 per share	0.67
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A
URGN Urogen Pharma	$109.79M	18.47	N/A	N/A	($2.25) per share	-18.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OCS Oculis	-$119.44M	-$1.74	N/A	N/A	N/A	-6,777.18%	-42.61%	-35.23%	11/5/2026 (Estimated)
PRGO Perrigo	-$1.43B	-$12.51	N/A	6.06	1.69	-41.85%	11.25%	4.08%	11/4/2026 (Estimated)
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	11/12/2026 (Estimated)
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	11.89	N/A	-51.73%	N/A	-43.79%	11/5/2026 (Estimated)

Latest OCS, PRGO, TRVI, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	OCS Oculis	-$0.48	-$0.20	+$0.28	-$0.20	$0.22 million	$0.38 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
8/5/2026	Q2 2026	PRGO Perrigo	$0.3880	$0.50	+$0.1120	$0.53	$1.02 billion	$1.02 billion
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
OCS Oculis	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	8.12%	+5.21%	N/A	23 Years
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Latest OCS, PRGO, TRVI, and URGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	PRGO Perrigo	quarterly	$0.29	7.98%	8/28/2026	8/28/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OCS Oculis	0.01	8.35	8.35
PRGO Perrigo	1.31	2.32	1.32
TRVI Trevi Therapeutics	N/A	37.28	37.28
URGN Urogen Pharma	N/A	3.80	3.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OCS Oculis	22.30%
PRGO Perrigo	95.91%
TRVI Trevi Therapeutics	95.76%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
OCS Oculis	N/A
PRGO Perrigo	0.40%
TRVI Trevi Therapeutics	15.39%
URGN Urogen Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OCS Oculis	60	57.98 million	N/A	Not Optionable
PRGO Perrigo	8,100	138.77 million	138.21 million	Optionable
TRVI Trevi Therapeutics	34	142.48 million	120.55 million	Optionable
URGN Urogen Pharma	291	48.88 million	46.54 million	Optionable

OCS, PRGO, TRVI, and URGN Headlines

Recent News About These Companies

Here's Why You Should Add URGN Stock to Your Portfolio Now

September 30 at 11:16 AM | zacks.com

UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base

September 25, 2026 | finance.yahoo.com

Bank of America Corp DE Acquires New Holdings in Urogen Pharma $URGN

September 25, 2026 | marketbeat.com

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

September 23, 2026 | finance.yahoo.com

Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from Analysts

September 17, 2026 | marketbeat.com

Urogen Pharma $URGN Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 14, 2026 | marketbeat.com

Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock

September 10, 2026 | insidertrades.com

Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock

September 9, 2026 | marketbeat.com

Jason Drew Smith Sells 1,519 Shares of Urogen Pharma (NASDAQ:URGN) Stock

September 9, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Trading Up 5.9% - Here's What Happened

September 9, 2026 | marketbeat.com

Urogen Pharma: Upside After Bladder Cancer Launch

September 9, 2026 | seekingalpha.com

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

September 8, 2026 | zacks.com

Legal & General Group Plc Invests $1.32 Million in Urogen Pharma $URGN

September 7, 2026 | marketbeat.com

Bank of New York Mellon Corp Buys New Position in Urogen Pharma $URGN

September 6, 2026 | marketbeat.com

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

UroGen Pharma to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Mark Schoenberg Sells 60,677 Shares of Urogen Pharma (NASDAQ:URGN) Stock

August 25, 2026 | insidertrades.com

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

August 21, 2026 | zacks.com

UroGen Pharma Earnings Call Highlights ZUSDURI Surge

August 20, 2026 | tipranks.com

UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform

August 20, 2026 | finance.yahoo.com

UroGen Pharma inks licensing deal with IntraGel Therapeutics

August 20, 2026 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, PRGO, TRVI, and URGN Company Descriptions

Oculis NASDAQ:OCS

$8.64 -0.12 (-1.37%)

As of 02:10 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Perrigo NYSE:PRGO

$14.29 +0.27 (+1.93%)

As of 02:11 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Trevi Therapeutics NASDAQ:TRVI

$13.92 -0.26 (-1.83%)

As of 02:11 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Urogen Pharma NASDAQ:URGN

$41.48 +0.93 (+2.30%)

As of 02:11 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCS, PRGO, TRVI, and URGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCS, PRGO, TRVI, and URGN Earnings

Compare Dividends

Latest OCS, PRGO, TRVI, and URGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCS, PRGO, TRVI, and URGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, PRGO, TRVI, and URGN Company Descriptions

Oculis NASDAQ:OCS

Perrigo NYSE:PRGO

Trevi Therapeutics NASDAQ:TRVI

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCS, PRGO, TRVI, and URGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCS, PRGO, TRVI, and URGN Earnings

Compare Dividends

Latest OCS, PRGO, TRVI, and URGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCS, PRGO, TRVI, and URGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, PRGO, TRVI, and URGN Company Descriptions

Oculis NASDAQ:OCS

Perrigo NYSE:PRGO

Trevi Therapeutics NASDAQ:TRVI

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools